« Previous
Next »
Journal of Surgical Research
Volume 140, Issue 1
, Pages 31-35
, 1 June 2007
The Use of Adjusted Preoperative CA 19-9 to Predict the Recurrence of Resectable Pancreatic Cancer
References
- Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastroint Surg. 2001;5:121
- Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. Ann Surg Oncol. 2001;8:123
- Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol. 1999;71:140
- . Role of tumor markers, cytogenetics. Ann Oncol. 1999;10:145
- Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol. 1988;6:462
- CA 19-9 as a prognostic index after resection for pancreatic cancer. J Surg Oncol. 1993;52:137
- Prediction of recurrence and survival by postresection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol. 1997;4:551
- Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract. Antimicrob Agents Chemother. 1996;40:2658
- Effect of biliary obstruction on the hepatic excretion of imipenem-cilastatin. Antimicrob Agents Chemother. 1992;36:2057
- . Utility of tumor marker in determining respectability of pancreatic cancer. Arch Surg. 2003;138:951
- . Cancer of the pancreas (Fifty years of surgery). Cancer. 1987;60:2284
- . Survival after pancreaticoduodenectomy (One hundred eighteen consecutive resections without an operative mortality). Ann Surg. 1990;211:447
- Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg. 1991;161:120
- . Pancreatic cancer: State-of-the-art care. CA Cancer Clin. 2000;50:241
- Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res. 1983;43:5489
- Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501
- Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetics. 1979;5:957
- Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82:1013
- . CA 19-9 is an index of response to neoadjuvant chemoradiation therapy in pancreatic cancer. Am J Surg. 1996;17:350
- . CA 19-9 levels predicts results of staging laparoscopy in pancreatic cancer. J Gastroint Surg. 2005;9:1286
- Serum CA 19-9 in the post surgical follow-up of patients with pancreatic cancer. Cancer. 1987;60:2428
- Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with respectable pancreatic adenocarcinoma. Ann Surg Oncol. 2004;11:644
- The clinical value of serum CEA, CA 19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Onco. 2005;31:164
PII: S0022-4804(06)00530-0
doi: 10.1016/j.jss.2006.10.007
© 2007 Elsevier Inc. All rights reserved.
« Previous
Next »
Journal of Surgical Research
Volume 140, Issue 1
, Pages 31-35
, 1 June 2007
